GSK, Spero to stop urinary tract infection drug trial due to early success
28/05/2025 12:10
May 28 (Reuters) - Spero Therapeutics SPRO.O and partner GSK GSK.L said on Wednesday that an experimental drug for complicated urinary tract infections met the main goal of a late-stage trial and the companies will be stopping the trial early for efficacy. (Reporting by Sriparna Roy in Bengaluru; Editing by Devika Syamnath) ((Sriparna.Roy@thomsonreuters.com;))
Recent news on Spero Therapeutics
See all newsBrief: Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Spero Therapeutics - May Offer Up To $300 Million In Securities - SEC Filing
Brief: Spero Therapeutics Appoints Debra Jeske Zack, M.D., Ph.D., As Chief Medical Officer
Spero licenses Innovent's experimental immune disease drug for up to $1.1 billion
US FDA approves GSK's oral antibiotic for drug-resistant UTIs (updated)